179 related articles for article (PubMed ID: 34345614)
21. Adult respiratory distress syndrome: do selective anticoagulants help?
Idell S
Am J Respir Med; 2002; 1(6):383-91. PubMed ID: 14720025
[TBL] [Abstract][Full Text] [Related]
22. The first case of COVID-19 treated with the complement C3 inhibitor AMY-101.
Mastaglio S; Ruggeri A; Risitano AM; Angelillo P; Yancopoulou D; Mastellos DC; Huber-Lang M; Piemontese S; Assanelli A; Garlanda C; Lambris JD; Ciceri F
Clin Immunol; 2020 Jun; 215():108450. PubMed ID: 32360516
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic Potential of Mesenchymal Stem Cells and Their Secretome in the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome.
Harrell CR; Jovicic BP; Djonov V; Volarevic V
Anal Cell Pathol (Amst); 2020; 2020():1939768. PubMed ID: 33274176
[TBL] [Abstract][Full Text] [Related]
24. Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series.
Hashemian SR; Aliannejad R; Zarrabi M; Soleimani M; Vosough M; Hosseini SE; Hossieni H; Keshel SH; Naderpour Z; Hajizadeh-Saffar E; Shajareh E; Jamaati H; Soufi-Zomorrod M; Khavandgar N; Alemi H; Karimi A; Pak N; Rouzbahani NH; Nouri M; Sorouri M; Kashani L; Madani H; Aghdami N; Vasei M; Baharvand H
Stem Cell Res Ther; 2021 Jan; 12(1):91. PubMed ID: 33514427
[TBL] [Abstract][Full Text] [Related]
25. Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome.
van de Veerdonk FL; Netea MG; van Deuren M; van der Meer JW; de Mast Q; Brüggemann RJ; van der Hoeven H
Elife; 2020 Apr; 9():. PubMed ID: 32338605
[TBL] [Abstract][Full Text] [Related]
26. Novel Coronavirus Disease 2019 (COVID-19) and Cytokine Storms for More Effective Treatments from an Inflammatory Pathophysiology.
Yokota S; Miyamae T; Kuroiwa Y; Nishioka K
J Clin Med; 2021 Feb; 10(4):. PubMed ID: 33671159
[TBL] [Abstract][Full Text] [Related]
27. Complement-mediated microvascular injury and thrombosis in the pathogenesis of severe COVID-19: A review.
Gianni P; Goldin M; Ngu S; Zafeiropoulos S; Geropoulos G; Giannis D
World J Exp Med; 2022 Jul; 12(4):53-67. PubMed ID: 36157337
[TBL] [Abstract][Full Text] [Related]
28. Complement profile.
Staicu I
Nat Immunol; 2024 Mar; 25(3):382. PubMed ID: 38429455
[No Abstract] [Full Text] [Related]
29. The case of complement inhibitors.
Noris M
Adv Biol Regul; 2021 Aug; 81():100822. PubMed ID: 34454870
[TBL] [Abstract][Full Text] [Related]
30. Complement and the prothrombotic state.
Schmidt CQ; Schrezenmeier H; Kavanagh D
Blood; 2022 Mar; 139(13):1954-1972. PubMed ID: 34415298
[TBL] [Abstract][Full Text] [Related]
31. COVID-19-associated atypical hemolytic uremic syndrome and use of Eculizumab therapy.
Gill J; Hebert CA; Colbert GB
J Nephrol; 2022 Jan; 35(1):317-321. PubMed ID: 34427905
[TBL] [Abstract][Full Text] [Related]
32. How we('ll) treat paroxysmal nocturnal haemoglobinuria: diving into the future.
Risitano AM; Peffault de Latour R
Br J Haematol; 2022 Jan; 196(2):288-303. PubMed ID: 34355382
[TBL] [Abstract][Full Text] [Related]
33. Comparative effectiveness of pegcetacoplan versus ravulizumab in patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a matching-adjusted indirect comparison.
Bhak RH; Mody-Patel N; Baver SB; Kunzweiler C; Yee CW; Sundaresan S; Swartz N; Duh MS; Krishnan S; Sarda SP
Curr Med Res Opin; 2021 Nov; 37(11):1913-1923. PubMed ID: 34445916
[TBL] [Abstract][Full Text] [Related]
34. A Conformational Change of Complement C5 Is Required for Thrombin-Mediated Cleavage, Revealed by a Novel Ex Vivo Human Whole Blood Model Preserving Full Thrombin Activity.
Nilsson PH; Johnson C; Quach QH; Macpherson A; Durrant O; Pischke SE; Fure H; Landsem A; Bergseth G; Schjalm C; Haugaard-Kedström LM; Huber-Lang M; van den Elsen J; Brekke OL; Mollnes TE
J Immunol; 2021 Sep; 207(6):1641-1651. PubMed ID: 34380648
[TBL] [Abstract][Full Text] [Related]
35. Eculizumab as a New Treatment for Severe Acute Post-infectious Glomerulonephritis: Two Case Reports.
Chehade H; Guzzo G; Cachat F; Rotman S; Teta D; Pantaleo G; Sadallah S; Sharma A; Rosales IA; Tolkoff-Rubin N; Pascual M
Front Med (Lausanne); 2021; 8():663258. PubMed ID: 34381795
[TBL] [Abstract][Full Text] [Related]
36. The Complement System: A Powerful Modulator and Effector of Astrocyte Function in the Healthy and Diseased Central Nervous System.
Pekna M; Pekny M
Cells; 2021 Jul; 10(7):. PubMed ID: 34359981
[TBL] [Abstract][Full Text] [Related]
37. Monoclonal Antibody Therapy in Neuromyelitis Optica Spectrum Disorders: a Meta-analysis of Randomized Control Trials.
Kong F; Wang J; Zheng H; Cai H; Hua J; Li L
Front Pharmacol; 2021; 12():652759. PubMed ID: 34354581
[TBL] [Abstract][Full Text] [Related]
38. Cellular changes in eculizumab early responders with generalized myasthenia gravis.
Li Y; Yi JS; Howard JF; Chopra M; Russo MA; Guptill JT
Clin Immunol; 2021 Oct; 231():108830. PubMed ID: 34450290
[TBL] [Abstract][Full Text] [Related]
39. Discontinuation of Eculizumab treatment after hematological remission in patients with atypical and drug-induced hemolytic uremic syndrome.
Yeter HH; Derici U; Arinsoy T; Altok K; Erten Y; Guz G
Rom J Intern Med; 2022 Mar; 60(1):56-65. PubMed ID: 34449174
[No Abstract] [Full Text] [Related]
40. Myelin-oligodendrocyte glycoprotein antibody-associated disease.
Marignier R; Hacohen Y; Cobo-Calvo A; Pröbstel AK; Aktas O; Alexopoulos H; Amato MP; Asgari N; Banwell B; Bennett J; Brilot F; Capobianco M; Chitnis T; Ciccarelli O; Deiva K; De Sèze J; Fujihara K; Jacob A; Kim HJ; Kleiter I; Lassmann H; Leite MI; Linington C; Meinl E; Palace J; Paul F; Petzold A; Pittock S; Reindl M; Sato DK; Selmaj K; Siva A; Stankoff B; Tintore M; Traboulsee A; Waters P; Waubant E; Weinshenker B; Derfuss T; Vukusic S; Hemmer B
Lancet Neurol; 2021 Sep; 20(9):762-772. PubMed ID: 34418402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
